Hannemann L, Reinhart K, Grenzer O, Meier-Hellmann A, Bredle D L
Department of Anesthesiology and Intensive Care Medicine, Free University of Berlin, Klinikum Benjamin Franklin, Germany.
Crit Care Med. 1995 Dec;23(12):1962-70. doi: 10.1097/00003246-199512000-00004.
To test whether dopamine infusion improves oxygen delivery (Do2) and oxygen uptake (VO2) in hyperdynamic septic shock patients stabilized by adequate volume and dobutamine alone, or by the combination of dobutamine and norepinephrine.
Prospective clinical trial of two patient groups. Group 1 (n = 15) was stabilized with dobutamine, and group 2 (n = 10) was stabilized with dobutamine and norepinephrine.
Intensive care unit in a university hospital.
Twenty-five postoperative, hyperdynamic septic shock patients.
The stabilizing catecholamine infusion was replaced in a stepwise manner by dopamine to achieve a similar mean arterial pressure (dopamine doses: group 1, mean 22 +/- 15 micrograms/kg/min [range 6 to 52]; and group 2, mean 57 +/- 41 micrograms/kg/min [range 15 to 130]).
A complete hemodynamic profile was performed with oxygen transport-related variables at baseline, after replacement by dopamine, and after resetting to the original catecholamine infusion. The change to dopamine resulted in increases in cardiac index (group 1: 20% [p < .01]; group 2: 33% [p < .01]), and DO2 (group 1: 19% [p < .01]; group 2: 27% [p < .01]). However, VO2, whether directly measured from the respiratory gases or calculated by the cardiovascular Fick principle, did not change in both groups with dopamine, while the oxygen extraction ratio decreased significantly in both groups with dopamine. Heart rate, pulmonary artery occlusion pressure, and pulmonary shunt fraction all increased with dopamine. PaO2 decreased, but oxygen saturation remained stable in both groups with dopamine.
Short-term dopamine infusion in hyperdynamic septic shock patients, despite producing higher global DO2, was not superior to dobutamine or the combination of dobutamine and norepinephrine infusion.
测试在仅通过充足容量及多巴酚丁胺或多巴酚丁胺与去甲肾上腺素联合治疗而病情稳定的高动力型感染性休克患者中,静脉输注多巴胺是否能改善氧输送(Do2)和氧摄取(VO2)。
对两组患者进行前瞻性临床试验。第1组(n = 15)采用多巴酚丁胺使其病情稳定,第2组(n = 10)采用多巴酚丁胺和去甲肾上腺素使其病情稳定。
一所大学医院的重症监护病房。
25例术后高动力型感染性休克患者。
逐步用多巴胺替代用于稳定病情的儿茶酚胺输注,以达到相似的平均动脉压(多巴胺剂量:第1组,平均22±15微克/千克/分钟[范围6至52];第2组,平均57±41微克/千克/分钟[范围15至130])。
在基线、用多巴胺替代后以及恢复至原儿茶酚胺输注后,对与氧输送相关的变量进行完整的血流动力学评估。改用多巴胺后,两组的心指数均增加(第1组:20%[p <.01];第2组:33%[p <.01]),Do2也增加(第1组:19%[p <.01];第2组:27%[p <.01])。然而,无论通过直接测量呼吸气体还是根据心血管菲克原理计算,两组患者使用多巴胺后VO2均未改变,而两组患者使用多巴胺后氧摄取率均显著降低。使用多巴胺后,心率、肺动脉闭塞压和肺分流分数均升高。两组患者使用多巴胺后PaO2降低,但氧饱和度保持稳定。
在高动力型感染性休克患者中短期输注多巴胺,尽管能产生更高的整体Do2,但并不优于输注多巴酚丁胺或多巴酚丁胺与去甲肾上腺素联合输注。